Skip to Content
Søg Menu

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

Charlotte Haslund, MD, chief oncologist at the Department of Oncology, Aalborg University Hospital, specializing in gynecological cancer, presented highlights and Danish perspectives on ovarian cancer at the Danish Evening at ESMO 2024.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
ESMO24Brystcancer

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynækologisk cancer

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungecancer

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungecancer
Josep M Llovet

Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

/ Josep M. Llovet
ESMO24Levercancer Play the Video 04:57

The Ultimate Proof That Immunotherapy Can Be Curative for Metastatic Malignant Melanoma

/ BestPractice Nordic
ESMO24Melanom

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top